Trial Profile
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 05 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
- 05 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jun 2019.